Fecha de publicación: 10/11/2021 Fuente: WIPO "propolis" The present invention discloses a novel standardized liquid propolis extract and pharmaceutical formulation based on said extract, their manufacturing methods and uses. The liquid extract is produced by extraction of crude propolis with an extraction solvent based on a mixture of PEG 200-600 (96.5-99.9% w/w) and lecithins (0.1-3.5% w/w). The extract is characterized with standardized content of p-coumaric acid (1), trans-ferulic acid (2), caffeic acid (3), and CAPE (4). It is used as an active ingredient in manufacturing of pharmaceutical, cosmetic, veterinary, agrochemical or functional food products. The pharmaceutical formulation according to the invention consists of 5-95% w/w of the said propolis extract and up to 100% excipients required for preparation of various dosage forms. It is used for treatment of diseases and conditions in humans and animals such as: inflammatory diseases, bacterial and fungal infections, viral, autoimmune and cancer diseases, and for the treatment of burns and wound healing.